Document Detail


The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure.
MedLine Citation:
PMID:  7074795     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hydralazine reduces pulmonary vascular resistance in patients with primary and secondary pulmonary hypertension, but the effects on right ventricular function of a change in resistance without a reduction in pulmonary arterial pressure are not known. We evaluated the hemodynamic effects of hydralazine, 50 mg, administered orally every 6 hours for 48 hours in 14 patients with right ventricular failure and pulmonary hypertension resulting from various causes. Hydralazine reduced mean right ventricular end-diastolic pressure from 17.4 +/- 5.6 to 11.6 +/- 5.3 mm Hg (p less than 0.001) and increased cardiac output and stroke volume by more than 40%. In nine patients who had no change in mean pulmonary arterial pressure after hydralazine, total pulmonary resistance decreased from 15.9 +/- 6.0 to 10.6 +/- 4.3 (p less than 0.001) and cardiac index increased from 2.07 +/- 0.51 to 2.97 +/- 0.91 (p less than 0.005). There was a close correlation between the reductions in total pulmonary resistance and right ventricular end-diastolic pressure (r = 0.73)). These data suggest that hydralazine can increase cardiac output and reduce right ventricular end-diastolic pressure even when pulmonary arterial pressure remains unchanged.
Authors:
L J Rubin; F Handel; R H Peter
Related Documents :
2520935 - The mechanism of nitrous oxide-induced changes in pulmonary vascular resistance in a do...
8842505 - Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial p...
1109705 - Early changes in lung water after haemorrhagic shock in pigs and dogs.
3698615 - Effect of bronchial blood flow on pulmonary artery wedge pressure with pulmonary embolism.
12832425 - Autonomic and vascular responses to reduced limb perfusion.
20484695 - Reduced systolic pressure load decreases cell-cycle activity in the fetal sheep heart.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  65     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1982 Jun 
Date Detail:
Created Date:  1982-07-22     Completed Date:  1982-07-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1369-73     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Arterioles / drug effects
Blood Pressure / drug effects*
Cardiac Output / drug effects
Female
Heart Failure / drug therapy*
Humans
Hydralazine / therapeutic use*
Hypertension, Pulmonary / drug therapy*
Lung / blood supply
Male
Middle Aged
Stroke Volume / drug effects
Vascular Resistance / drug effects
Grant Support
ID/Acronym/Agency:
HL-0719/HL/NHLBI NIH HHS; RR-30/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
86-54-4/Hydralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of verapamil and propranolol on left ventricular systolic function and diastolic filling in ...
Next Document:  Drug-induced conditioning in congestive heart failure.